Publications
Since the beginning the center participants has frwquently published their research findings and conclusions in worldwide highly esteemed journals. The ctDNA Center has many international collaborators with both academic and commercial partners and participates in multiple international ctDNA-focused networks and societies.
Below you will find a list with publications about ctDNA research done by center participants.
When you click at the title, you will be directed to the article.
51. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review
Simone Karlsson Terp, Malene Pontoppidan Stoico, Karen Dybkær, Inge Søkilde Pedersen
(2023, February). Clin Epigenet 15, 24 Doi: 10.1186/s13148-023-01440-w. PMID: 36788585
50. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer
Maibritt Nørgaard, Marianne T Bjerre, Jacob Fredsøe, Søren Vang, Jørgen B Jensen, Bram De Laere, Henrik Grönberg, Michael Borre, Johan Lindberg, Karina D Sørensen
(2023, February). Clinical Chemistry hvac224. Doi: 10.1093/clinchem/hvac224. PMID: 36762756
49. Cell-free urine-and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer
Emil Christensen, Iver Nordentoft, Karin Birkenhamp-Demtröder, Sara K. Elbæk, Sia V. Lindskrog, Ann Taber, Tine G. Andreasen, Trine Strandgaard, Michael Knudsen, Philippe Lamy, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt
(2023, February). Clinical Cancer Research, 13;CCR-22-3250. doi: 10.1158/1078-0432.CCR-22-3250. PMID: 36780195
48. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology
Anders K. M. Jakobsen, Karen-Lise Garm Spindler
(2023, February). European Journal of Cancer, 180. Pages 180-183. doi: 10.1016/j.ejca.2022.11.039. PMID: 36610263
47. Impact of Whole Genome Doubling on Dettection of Circulating Tumor DNA in Colorectal Cancer
Jonas Kabel, Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, Mads Heilskov Rasmussen, Jesper Nors, Nicolai J. Birkbak, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Thomas Kolbro, Alessio Monti, Ole Thorlacius-Ussing, Mikail Gögenur, Jeppe Kildsig, Nis Hallundbæk Schlesinger, Peter Bondeven, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Claus Lindbjerg Andersen
(2023, February). Cancers, 15(4), 1136. doi: 10.3390/cancers15041136. PMID: 36831479
46. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non–muscle-invasive Bladder Cancer
Trine Strandgaard; Sia Viborg Lindskrog; Iver Nordentoft; Emil Christensen; Karin Birkenkamp-Dermtröder; Trine Ginnerup Andreasen; Philippe Lamy; Asbjørn Kjær; Daniel Ranti; Yuan-Sho Wang; Christine Bieber; Frederik Prip; Julie Rasmussen; Torben Steiniche; Nicolai Birkbak; John Sfakianos; Amir Horowitz; Jørgen Bjerggaard Jensen; Lars Dyrskjøt
(2022, December). European Urology, 82(6). Pages 646-656. Doi: 10.1016/j.eururo.2022.09.008. PMID: 36210217
45. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis
Callesen LB, Takacova T, Hamfjord J, et al.
(2022, November). Therapeutic Advances in Medical Oncology, 14. doi:10.1177/17588359221133171. PMID: 36339929
44. Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour - A Methodological Assessment Study
Brinch CM, Aggerholm-Pedersen N, Poulsen TS, Skovrider-Ruminski W, DE Heer P, Penninga L, Krarup-Hansen A, Hogdall E.
(2022, November). Anticancer Res., 42(11):5527-5537. Doi: 10.21873/anticanres.16022. PMID: 36288871
43. Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced Non-Small Cell Lung Cancer patients
Frank M.S., Andersen C.S.A., Ahlborn L.B., Pallisgaard N., Bodtger U., Gehl J.
(2022, September). Cancer Research Communications. doi: 10.1158/2767-9764.CRC-22-0258
42. Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy
Truelsen CG, Kronborg CS, Sørensen BS, Callesen LB, Spindler KG.
(2022, September). Clinical and Translational Radiation Oncology, 36. Pages 9-15. doi: 10.1016/j.ctro.2022.06.002. PMID: 35733829
41. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol
Callesen LB, Hansen TF, Andersen RF, Pallisgaard N, Kramer S, Schlander S, Rafaelsen SR, Boysen AK, Jensen LH, Jakobsen A, Spindler KG.
(2022, September). Acta Oncoloca, 12:1-5. doi: 10.1080/0284186X.2022.2116728. PMID: 36094310
40. ctDNA-Guided Adjuvant Chemotherapy for Colorectal Cancer - Ready for Prime Time
Andersen, CL; Heitzer, E.
(2022, September). Cancer Cell, 40(9). Pages 911-913. doi: 10.1016/j.ccell.2022.08.017. PMID: 36055230
39. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG.
(2022, August). British Journal of Cancer, 127(3). Pages 500-513. doi: 10.1038/s41416-022-01816-4. PMID: 35440666
38. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis
Gögenur M, Hadi NA, Qvortrup C, Andersen CL, Gögenur I.
(2022, August). Annals of Surgical Oncology. doi: 10.1245/s10434-022-12366-7. PMID: 35933546
37. Comparing Single-target and Multitarget Approaches for Postoperative Tumour DNA Detection in Stage II-III Colorectal Cancer Patients
Henriksen, T. V., Reinert, T., Rasmussen, M. H., Demuth, C., Løve, U. S., Madsen, A. H., Gotschalck, K. A., Iversen, L. H., & Andersen, C. L.
(2022, July). Molecular Oncology. doi: 10.1002/1878-0261.13294. PMID: 35895438
36. Unsupervised Detection of Fragment Length Signatures of Circulating Tumor DINA using non-negative Metrix Factorization
Reanud, G., Nørgaard, M., Lindberg, J., Grönberg, H., De Laere, B., Jensen, J. B., Borre, M., Andersen, C. L., Sørensen, K. D., Maretty, L. & Besenbacher, S.
(2022, July). Elife, 11, e71569. doi: 10.7554/eLife.71569. PMID: 35894300
35. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
Bønløkke S, Stougaard M, Sorensen BS, Booth BB, Høgdall E, Nyvang GB, Lindegaard JC, Blaakær J, Bertelsen J, Fuglsang K, Strube ML, Lenz S, Steiniche T.
(2022, July). Cells, 11(14):2170. Doi: 10.3390/cells11142170. PMID: 35883612
34. Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
Thomsen, C.B, Juul, A.D., Lefèvre, A.C., Truelsen, C.G., Dizdarevic, E., Ryssel, H., Kjær, I.M., Wind, K.L., Callesen, L.B., Larsen, L.F., Frank, M.S., Andersen, R.F., Spindler, K.G., Jakobsen, A.
(2022, June). Cancer, 128(11). Pages 2052-2057. doi: 10.1002/cncr.34168. PMID: 35302663
33. Error characterization and statistical modeling improves Circulating Tumor DNA detection by droplet digital PCR
Henriksen, T. V., Drue, S. O., Frydendahl, A., Demuth, C., Rasmussen, M. H., Reinert, T., Pedersen, J. S. & Andersen, C. L
(2022, May). Clinical Chemistry, 68(5). Pages 657-667. doi: 10.1093/clinchem/hvab274. PMID: 35030248
32. Circulating Tumor DNA for Prognosis and Postoperative Management after Curative-intent Resection of Colorectal Liver Metastases
Reinert, T., Petersen, L. M. S., Henriksen, T. V., Larsen, M. Ø., Rasmussen, M. H., Johansen, A. F. B., Øgaard, N., Knudsen, M., Nordentoft, I., Vang, S., Krag, S. R. P., Knudsen, A. R., Mortensen, F. V. & Andersen, C. L.
(2022, May). International Journal of Cancer, 150(9). Pages 1537-1548. doi: 10.1002/ijc.33924. PMID: 34994972
31. Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer-A Systematic Review
Wen SWC, Wen J, Hansen TF, Jakobsen A, Hilberg O.
(2022, April). Cancers (Basel), 14(9):2254. Doi: 10.3390/cancers14092254. PMID: 35565384
30. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
Dizdarevic E, Hansen TF, Jakobsen A.
(2022, April). Cancers (Basel), 14(9):2252. Doi: 10.3390/cancers14092252. PMID: 35565381
29. Total cell-free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay
Callesen LB, Sørensen BS, Pallisgaard N, Laugesen IG, Boysen AK, Spindler KG.
(2022, March). Molecular and Clinical Oncology, 16(3). Pages 64. doi: 10.3892/mco.2022.2497. PMID: 35154704
28. Tumor-agnostic circulating tumor DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: a prospective cohort study
Øgaard N., Reinert T., Henriksen T.V., Frydendahl A., Aagaard E., Ørntoft MB. W., Larsen M.Ø., Knudsen A.R., Mortensen F.V., Andersen C.L.
(2022, March). European Journal of Cancer, 163. Pages 163-176. doi: 10.1016/j.ejca.2021.12.026. PMID: 35074652
27. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study
Pommergaard HC, Yde CW, Ahlborn LB, Andersen CL, Henriksen TV, Hasselby JP, Rostved AA, Sørensen CL, Rohrberg KS, Nielsen FC, Rasmussen A.
(2022, February). Molecular Biology Reports, 49(2). Pages 1609-1616. doi: 10.1007/s11033-021-06962-1. PMID: 34811635
26. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Roselló, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes and Claus Lindbjerg Andersen
(2022, February). Clinical Cancer Research, 28(3). Pages 507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408
25. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma
Stubbe, B.E.; Henriksen, S.D.; Madsen, P.H.; Larsen, A.C.; Krarup, H.B.; Pedersen, I.S.; Johansen, M.N.; Thorlacius-Ussing, O.
(2021, November). Cancers, 13(22). Pages 5717. doi: 10.3390/cancers13225717. PMID: 34830873
24. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement
Faaborg L, Fredslund Andersen R, Waldstrøm M, Høgdall E, Høgdall C, Adimi P, Jakobsen A, Dahl Steffensen K.
(2021, November). Clin Chim Acta., 522:152-157. Doi: 10.1016/j.cca.2021.08.020. Epub 2021 Aug 19. PMID: 34419462
23. Investigation of circulating DNA integrity after blood collection
Oriane C., Veyhe S.R., Hansen M.H., Titlestad K., and Nyvold C.G.
(2021, October). BioTechniques, 71(5). Pages 550-555. doi: 10.2144/btn-2020-0167. PMID: 34645292
22. Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L, Adleff V, Chiao JY, Leal A, Noe M, White JR, Arun AS, Hruban C, Annapragada AV, Jensen SØ, Ørntoft MW, Madsen AH, Carvalho B, de Wit M, Carey J, Dracopoli NC, Maddala T, Fang KC, Hartman AR, Forde PM, Anagnostou V, Brahmer JR, Fijneman RJA, Nielsen HJ, Meijer GA, Andersen CL, Mellemgaard A, Bojesen SE, Scharpf RB, Velculescu VE.
(2021, August). Nat Commun., 12(1):5060. Doi: 10.1038/s41467-021-24994-w. PMID: 34417454
21. Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
Wen SWC, Andersen RF, Rasmussen K, Thomsen CB, Hansen TF, Nederby L, Hager H, Jakobsen A, Hilberg O.
(2021, August). Cancers (Basel), 13(16):4223. Doi: 10.3390/cancers13164223. PMID: 34439376
20. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
Jensen SG, Epistolio S, Madsen CL, Kyneb MH, Riva A, Paganotti A, Barizzi J, Petersen RK, Børgesen M, Molinari F, Boldorini R, Lorenzen J, Sørensen E, Christensen UB, Høgdall E, Frattini M.
(2021, June). PLoS One, 16(6):e0253687. Doi: 10.1371/journal.pone.0253687. eCollection 2021. PMID: 34166445
19. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study
Henriksen SD, Stubbe BE, Madsen PH, Johansen JS, Jensen BV, Hansen CP, Johansen MN,
Pedersen IS, Krarup H, Thorlacius-Ussing O.
(2021, May). Pancreatology 8:S1424-3903(21)00154-X. Doi: 10.1016/j.pan.2021.05.003. Online
ahead of print. PMID: 33994313
18. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus
Lefèvre AC, Pallisgaard N, Kronborg C, Wind KL, Krag SRP, Spindler KG.
(2021, May). Cancers,13(10). Pages 2451. doi: 10.3390/cancers13102451. PMID: 34070045
17. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update
Henriksen SD, Thorlacius-Ussing O.
(2021, April). Epigenomes, 9;5(2):8. Doi: 10.3390/epigenomes5020008. PMID: 34968295
16. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival
Jakobsen A, Andersen RF, Hansen TF, Jensen LH, Faaborg L, Steffensen KD, Thomsen CB, Wen SWC.
(2021, April). European Journal of Cancer, 149. Pages 128-133. doi: 10.1016/j.ejca.2021.03.006. PMID: 33857886
15. Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer
Tarpgaard LS, Andersen PV, Øgaard N, Demuth C, Andersen CL, Pfeiffer P.
(2021, March). Annals of Oncololy, 32(6). Pages 805-806. doi: 10.1016/j.annonc.2021.03.001. PMID: 33727198
14. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
Wen SWC, Andersen RF, Hansen TF, Nyhus CH, Hager H, Hilberg O, Jakobsen A.
(2021, February). Translational Lung Cancer Reserch, 10(2). Pages 855-865. doi: 10.21037/tlcr-20-826. PMID: 33718027
13. Quantifying sequencing error and effective sequencing depth of liquid biopsy NGS with UMI error correction
Frank, M.S., Fuß, J., Steiert, T.A., Streleckiene, G., Gehl, J., Forster, M.
(2021, January). BioTechniques, 70(4). doi: 10.2144/btn-2020-0124. PMID: 33512245
12. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer
Young GP, Symonds EL, Nielsen HJ, Ferm L, Christensen IJ, Dekker E, van der Vlugt M, Mallant-Hent RC, Boulter N, Yu B, Chan M, Tevz G, LaPointe LC, Pedersen SK.
(2021, January). Clin Epigenetics, 13(1):14. Doi: 10.1186/s13148-020-00999-y. PMID: 33478584
11. Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
Wen SWC, Andersen RF, Petersen LMS, Hager H, Hilberg O, Jakobsen A, Hansen TF.
(2020, December). Cancers, 12(12). Pages 3728. doi: 10.3390/cancers12123728. PMID: 33322500
10. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer
Ørntoft MW, Jensen SØ, Øgaard N, Henriksen TV, Ferm L, Christensen IJ, Reinert T, Larsen OH, Nielsen HJ, Andersen CL. I
(2020, December). International Journal of Cancer, 148(7). Pages 1665-1675. doi: 10.1002/ijc.33434. PMID: 33320961
9. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
Boysen AK, Pallisgaard N, Andersen CSA, Spindler KG.
(2020, August). Acta Oncologia, 59(12). Pages 1424-1429. doi: 10.1080/0284186X.2020.1806357. PMID: 32790489
8. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion
Sarah Ø Jensen, Nadia Øgaard, Hans Jørgen Nielsen, Jesper B Bramsen, Claus L Andersen
(2020, July). Clinical Chemistry, 66(7). Pages 925-933. doi: 10.1093/clinchem/hvaa100. PMID: 32460325
7. The effect of surgical trauma on circulating free DNA levels in cancer patients - implications for studies of circulating tumor DNA
Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtröder K, Gögenur M, Gögenur I, Zimmermann BG; IMPROVE Study Group, Dyrskjøt L, Andersen CL.
(2020, May). Molecular Oncology, 14(8). Pages 1670-1679. doi: 10.1002/1878-0261.12729. PMID: 32471011
6. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations
Nygård L, Ahlborn LB, Persson GF, Chandrananda D, Langer JW, Fischer BM, Langer SW, Gabrielaite M, Kjær A, Rosenfeld N, Mouliere F, Østrup O, Vogelius IR, Bentzen SM.
(2020, April). PLoS One, 15(4). doi: 10.1371/journal.pone.0231884. PMID: 32343749. PMCID: PMC7188247
5. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)
Skougaard K, Østrup O, Guldbrandsen K, Sørensen B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson G, Land LH, Schytte T, Bodtger U, Skuladottir H, Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM.
(2020, March). Clinical Lung Cancer, 21(2). Pages e61-e64. doi: 10.1016/j.cllc.2019.11.002. PMID: 31839533
4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study
Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U.
(2019, July). Oncotarget, 10(43). Pages 4397-4406. doi: 10.18632/oncotarget.27030. PMID: 31320993. PMCID: PMC6633897
3. Toward liquid biopsies in cancer treatment: Application of circulating tumor DNA
Barlebo Ahlborn L, Østrup O.
(2019, May). APMIS, 127(5). Pages 329-336. doi: 10.1111/apm.12912. PMID: 30784124
2. IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol
Jesper Nors, Tenna Vesterman Henriksen, Kåre Andersson Gotschalck, Therese Juul, Jes Søgaard, Lene Hjerrild Iversen, Claus Lindbjerg Andersen
(2020, March). Acta Oncologica, 59(3). Pages 336-341. Doi: 10.1080/0284186X.2019.1711170. PMID: 31920137
1. Application of cell-free DNA for genomic tumor profiling: A feasibility study
Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O.
(2019, February). Oncotarget, 10(14). Pages 1388-1398. doi: 10.18632/oncotarget.26642. PMID: 30858924. PMCID: PMC6402712
Contact Anne Lærke Lorentzen, Scientific Coordiantor, if you have publications for the list
E-mail: anne.lorentzen@clin.au.dk
Phone: +45 78 45 53 39